Pulmonx (LUNG) Q2 Revenue Rises 15%
Pulmonx (NASDAQ:LUNG), a medical technology firm specializing in minimally invasive treatments for severe lung diseases, reported earnings for Q2 2025 on July 30, 2025. The company topped revenue expectations with $23.9 million in GAAP revenue, just above the $23.74 million analyst consensus (GAAP), representing an increase of 14.8% compared to Q2 2024. Its net loss per share (GAAP) narrowed to $(0.38) and improving slightly from $(0.39) in Q2 2024. However, despite strong international results, management revised full-year 2025 revenue guidance down by $6 million, now targeting $90–$92 million for the year. Operating discipline helped keep expenses in check, but profit levels (GAAP) did not materially improve. While gross profit and international sales grew, slow U.S. traction and gross margin pressure weighed on the overall quarter.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Pulmonx develops and markets devices for severe emphysema—a serious form of chronic obstructive pulmonary disease (COPD). Its main product family is the Zephyr Endobronchial Valve, a tiny, implantable medical device designed to help people with advanced lung disease breathe better by blocking targeted areas of damaged lung.
Source Fool.com
